E-cigarettes fail to help cancer patients kick the butt

Image
Press Trust of India Washington
Last Updated : Sep 22 2014 | 5:15 PM IST
Cancer patients who use e-cigarettes to help them quit smoking may actually end up more dependent on nicotine than non-users, a new study has found.
Researchers found that cancer patients who use e-cigarettes (in addition to traditional cigarettes) are more nicotine dependent and are equally or less likely to quit smoking traditional cigarettes than non-users.
To examine available clinical data about e-cigarette use and cessation among cancer patients, Jamie Ostroff, of the Memorial Sloan Kettering Cancer Center in New York City, and her colleagues studied 1074 cancer patients who smoked and were enrolled between 2012 and 2013 in a tobacco treatment programme within a comprehensive cancer center.
The researchers observed a three-fold increase in e-cigarette use from 2012 to 2013 (10.6 per cent versus 38.5 per cent).
At enrolment, e-cigarette users were more nicotine dependent than non-users, had more prior quit attempts, and were more likely to be diagnosed with lung or head and neck cancers.
At follow-up, e-cigarette users were just as likely as non-users to be smoking.
Seven day abstinence rates were 44.4 per cent versus 43.1 per cent for e-cigarette users and non-users, respectively.
"Consistent with recent observations of increased e-cigarette use in the general population, our findings illustrate that e-cigarette use among tobacco-dependent cancer patients has increased within the past two years," said Ostroff.
"Controlled research is needed to evaluate the potential harms and benefits of e-cigarettes as a potential cessation approach for cancer patients.
"In the meantime, oncologists should advise all smokers to quit smoking traditional combustible cigarettes, encourage use of FDA-approved cessation medications, refer patients for smoking cessation counselling, and provide education about the potential risks and lack of known benefits of long-term e-cigarette use," Ostroff said.
The findings were published in the journal Cancer.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 22 2014 | 5:15 PM IST

Next Story